Veradigm Financials
Financial Health Signals
Based on FY2022 annual data. Scores normalized against common benchmarks. How we calculate these scores
Veradigm has an operating margin of -4.6%, meaning the company retains $-5 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from 13.3% the prior year.
Veradigm's revenue grew a modest 1.8% year-over-year to $588.0M. This slow but positive growth earns a score of 34/100.
Veradigm carries a low D/E ratio of 0.20, meaning only $0.20 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.95, Veradigm holds $2.95 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 98/100.
Veradigm converts 19.3% of revenue into free cash flow ($113.5M). This strong cash generation earns a score of 97/100.
Veradigm passes 7 of 9 financial strength tests. 2 of 4 profitability signals pass, all 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Veradigm generates $-1.34 in operating cash flow ($115.6M OCF vs -$86.5M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Veradigm earns $-4.3 in operating income for every $1 of interest expense (-$27.1M vs $6.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Veradigm (MDRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Veradigm generated $588.0M in revenue in fiscal year 2022. This represents an increase of 1.8% from the prior year.
Veradigm's EBITDA was $88.8M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 40.6% from the prior year.
Veradigm generated $113.5M in free cash flow in fiscal year 2022, representing cash available after capex. This represents an increase of 244.6% from the prior year.
Veradigm reported -$86.5M in net income in fiscal year 2022. This represents a decrease of 162.0% from the prior year.
Veradigm earned $-0.77 per diluted share (EPS) in fiscal year 2022. This represents a decrease of 176.2% from the prior year.
Veradigm held $446.6M in cash against $200.4M in long-term debt as of fiscal year 2022.
Veradigm had 106M shares outstanding in fiscal year 2022. This represents a decrease of 8.6% from the prior year.
Veradigm's gross margin was 52.4% in fiscal year 2022, indicating the percentage of revenue retained after direct costs. This is up 3.5 percentage points from the prior year.
Veradigm's operating margin was -4.6% in fiscal year 2022, reflecting core business profitability. This is down 17.9 percentage points from the prior year.
Veradigm's net profit margin was -14.7% in fiscal year 2022, showing the share of revenue converted to profit. This is down 38.9 percentage points from the prior year.
Veradigm invested $97.9M in research and development in fiscal year 2022. This represents an increase of 16.4% from the prior year.
Veradigm spent $234.4M on share buybacks in fiscal year 2022, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 43.8% from the prior year.
Veradigm invested $2.1M in capex in fiscal year 2022, funding long-term assets and infrastructure. This represents an increase of 8.9% from the prior year.
MDRX Income Statement
| Metric | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 | Q1'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $156.2M+6.7% | $146.4M-1.4% | $148.5M+8.4% | $136.9M-12.9% | $157.2M+8.9% | $144.4M+2.4% | $141.0M+4.6% | $134.8M |
| Cost of Revenue | $69.4M-0.1% | $69.4M-3.4% | $71.9M+4.3% | $68.9M-6.6% | $73.8M-3.9% | $76.8M+4.7% | $73.4M+3.3% | $71.0M |
| Gross Profit | $86.9M+12.8% | $77.0M+0.5% | $76.6M+12.6% | $68.0M-18.5% | $83.4M+23.3% | $67.6M0.0% | $67.7M+6.1% | $63.8M |
| R&D Expenses | $27.0M+7.8% | $25.0M+8.2% | $23.1M+1.8% | $22.7M+6.1% | $21.4M-2.6% | $22.0M+6.9% | $20.6M+2.4% | $20.1M |
| SG&A Expenses | $43.7M+13.3% | $38.5M-9.1% | $42.4M-5.1% | $44.7M+81.3% | $24.6M-12.7% | $28.2M+1.0% | $27.9M-9.7% | $31.0M |
| Operating Income | -$9.5M+1.0% | -$9.6M-111.3% | -$4.5M-26.7% | -$3.6M-110.2% | $35.2M+139.5% | $14.7M-11.5% | $16.6M+60.2% | $10.4M |
| Interest Expense | $1.1M-12.9% | $1.2M-34.0% | $1.9M-11.7% | $2.1M-38.2% | $3.5M-4.4% | $3.6M+22.7% | $2.9M+1.6% | $2.9M |
| Income Tax | $18.0M+278.1% | -$10.1M+64.0% | -$28.0M-18.5% | -$23.7M-235.6% | $17.4M+193.8% | $5.9M+65.2% | $3.6M+22.2% | $2.9M |
| Net Income | -$26.6M-5574.1% | -$468K+99.4% | -$83.0M-452.2% | $23.6M-67.9% | $73.5M+354.4% | $16.2M-26.2% | $21.9M+142.1% | $9.1M |
| EPS (Diluted) | $-0.25-2400.0% | $-0.01+98.6% | $-0.73-529.4% | $0.17-70.2% | $0.57+418.2% | $0.11-50.0% | $0.22+57.1% | $0.14 |
MDRX Balance Sheet
| Metric | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 | Q1'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.5B-11.0% | $1.7B-1.4% | $1.7B-29.5% | $2.4B+5.2% | $2.3B-7.0% | $2.5B-2.2% | $2.5B-11.5% | $2.9B |
| Current Assets | $679.6M-16.2% | $810.8M-2.2% | $828.8M-46.2% | $1.5B+137.3% | $649.2M-19.3% | $805.0M-4.3% | $841.0M-25.9% | $1.1B |
| Cash & Equivalents | $446.6M-9.3% | $492.6M-1.5% | $500.2M+504.2% | $82.8M-38.1% | $133.7M-6.1% | $142.3M-10.8% | $159.6M-64.8% | $453.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $119.1M-29.5% | $169.0M+1.4% | $166.7M-2.2% | $170.5M+42.4% | $119.7M-64.9% | $340.9M+0.7% | $338.6M-5.7% | $359.1M |
| Goodwill | $532.6M+1.7% | $523.9M0.0% | $524.1M+0.8% | $520.2M+4.4% | $498.4M-48.9% | $974.4M0.0% | $974.8M0.0% | $974.8M |
| Total Liabilities | $487.2M-5.1% | $513.6M-0.8% | $517.9M-51.9% | $1.1B+13.3% | $950.6M-10.8% | $1.1B-7.1% | $1.1B-3.8% | $1.2B |
| Current Liabilities | $230.3M-9.0% | $253.1M-1.3% | $256.3M-60.4% | $646.9M+32.4% | $488.4M-13.8% | $566.9M-4.9% | $596.1M-32.3% | $880.3M |
| Long-Term Debt | $200.4M0.0% | $200.3M+0.2% | $199.9M-47.0% | $377.1M+7.7% | $350.1M-6.2% | $373.2M-11.4% | $421.3M+148.6% | $169.4M |
| Total Equity | $1.0B-13.6% | $1.2B-1.6% | $1.2B-11.6% | $1.4B-0.5% | $1.4B-4.1% | $1.4B+1.8% | $1.4B-17.0% | $1.7B |
| Retained Earnings | $645.8M-14.3% | $753.4M+2.0% | $738.9M-8.0% | $802.9M+11.5% | $719.8M+5.8% | $680.3M+2.4% | $664.1M+3.4% | $642.2M |
MDRX Cash Flow Statement
| Metric | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 | Q1'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $19.8M-29.7% | $28.1M+1821.2% | -$1.6M-102.4% | $69.3M+8.5% | $63.9M+14.3% | $55.9M+127.8% | -$200.9M-4492.1% | $4.6M |
| Capital Expenditures | $186K-17.0% | $224K-82.9% | $1.3M+278.8% | $345K-59.1% | $843K+2.2% | $825K | $0-100.0% | $225K |
| Free Cash Flow | $19.6M-29.8% | $27.9M+1048.9% | -$2.9M-104.3% | $68.9M+9.4% | $63.0M+14.4% | $55.1M+127.4% | -$200.9M-4719.2% | $4.3M |
| Investing Cash Flow | -$18.6M-100.7% | -$9.3M-101.4% | $657.2M+1586.8% | -$44.2M-204.8% | $42.2M+307.5% | -$20.3M-30.7% | -$15.6M+18.1% | -$19.0M |
| Financing Cash Flow | -$57.5M-49.6% | -$38.5M+86.6% | -$286.0M-354.1% | -$63.0M+52.9% | -$133.5M-166.7% | -$50.1M+26.1% | -$67.7M-801.3% | -$7.5M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $57.4M+70.5% | $33.7M-64.1% | $93.7M+88.6% | $49.7M-54.2% | $108.5M | $0-100.0% | $309.0M | $0 |
MDRX Financial Ratios
| Metric | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 | Q1'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 55.6%+3.0pp | 52.6%+1.0pp | 51.6%+1.9pp | 49.7%-3.4pp | 53.0%+6.2pp | 46.8%-1.1pp | 48.0%+0.7pp | 47.3% |
| Operating Margin | -6.1%+0.5pp | -6.5%-3.5pp | -3.0%-0.4pp | -2.6%-25.0pp | 22.4%+12.2pp | 10.2%-1.6pp | 11.8%+4.1pp | 7.7% |
| Net Margin | -17.0%-16.7pp | -0.3%+55.6pp | -55.9%-73.1pp | 17.2%-29.6pp | 46.8%+35.6pp | 11.2%-4.3pp | 15.6%+8.8pp | 6.7% |
| Return on Equity | N/A | N/A | N/A | 1.7%-3.7pp | 5.4%+4.3pp | 1.1%-0.4pp | 1.6%+1.0pp | 0.5% |
| Return on Assets | -1.8%-1.7pp | -0.0%+4.8pp | -4.8%-5.8pp | 1.0%-2.2pp | 3.2%+2.5pp | 0.7%-0.2pp | 0.9%+0.5pp | 0.3% |
| Current Ratio | 2.95-0.3 | 3.20-0.0 | 3.23+0.9 | 2.38+1.1 | 1.33-0.1 | 1.420.0 | 1.41+0.1 | 1.29 |
| Debt-to-Equity | 0.20+0.0 | 0.170.0 | 0.17-0.1 | 0.28+0.0 | 0.260.0 | 0.26-0.0 | 0.30+0.2 | 0.10 |
| FCF Margin | 12.6%-6.5pp | 19.1%+21.1pp | -2.0%-52.3pp | 50.3%+10.2pp | 40.1%+2.0pp | 38.1%+180.6pp | -142.5%-145.7pp | 3.2% |
Similar Companies
Frequently Asked Questions
What is Veradigm's annual revenue?
Veradigm (MDRX) reported $588.0M in total revenue for fiscal year 2022. This represents a 1.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Veradigm's revenue growing?
Veradigm (MDRX) revenue grew by 1.8% year-over-year, from $577.4M to $588.0M in fiscal year 2022.
Is Veradigm profitable?
No, Veradigm (MDRX) reported a net income of -$86.5M in fiscal year 2022, with a net profit margin of -14.7%.
What is Veradigm's earnings per share (EPS)?
Veradigm (MDRX) reported diluted earnings per share of $-0.77 for fiscal year 2022. This represents a -176.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Veradigm's EBITDA?
Veradigm (MDRX) had EBITDA of $88.8M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Veradigm have?
As of fiscal year 2022, Veradigm (MDRX) had $446.6M in cash and equivalents against $200.4M in long-term debt.
What is Veradigm's gross margin?
Veradigm (MDRX) had a gross margin of 52.4% in fiscal year 2022, indicating the percentage of revenue retained after direct costs of goods sold.
What is Veradigm's operating margin?
Veradigm (MDRX) had an operating margin of -4.6% in fiscal year 2022, reflecting the profitability of core business operations before interest and taxes.
What is Veradigm's net profit margin?
Veradigm (MDRX) had a net profit margin of -14.7% in fiscal year 2022, representing the share of revenue converted into profit after all expenses.
What is Veradigm's free cash flow?
Veradigm (MDRX) generated $113.5M in free cash flow during fiscal year 2022. This represents a 244.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Veradigm's operating cash flow?
Veradigm (MDRX) generated $115.6M in operating cash flow during fiscal year 2022, representing cash generated from core business activities.
What are Veradigm's total assets?
Veradigm (MDRX) had $1.5B in total assets as of fiscal year 2022, including both current and long-term assets.
What are Veradigm's capital expenditures?
Veradigm (MDRX) invested $2.1M in capital expenditures during fiscal year 2022, funding long-term assets and infrastructure.
How much does Veradigm spend on research and development?
Veradigm (MDRX) invested $97.9M in research and development during fiscal year 2022.
Does Veradigm buy back shares?
Yes, Veradigm (MDRX) spent $234.4M on share buybacks during fiscal year 2022, returning capital to shareholders by reducing shares outstanding.
How many shares does Veradigm have outstanding?
Veradigm (MDRX) had 106M shares outstanding as of fiscal year 2022.
What is Veradigm's current ratio?
Veradigm (MDRX) had a current ratio of 2.95 as of fiscal year 2022, which is generally considered healthy.
What is Veradigm's debt-to-equity ratio?
Veradigm (MDRX) had a debt-to-equity ratio of 0.20 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Veradigm's return on assets (ROA)?
Veradigm (MDRX) had a return on assets of -5.8% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.
What is Veradigm's Piotroski F-Score?
Veradigm (MDRX) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Veradigm's earnings high quality?
Veradigm (MDRX) has an earnings quality ratio of -1.34x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Veradigm cover its interest payments?
Veradigm (MDRX) has an interest coverage ratio of -4.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Veradigm?
Veradigm (MDRX) scores 66 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.